These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 28452365)
21. Cyclodextrin mediates rapid changes in lipid balance in Npc1-/- mice without carrying cholesterol through the bloodstream. Taylor AM; Liu B; Mari Y; Liu B; Repa JJ J Lipid Res; 2012 Nov; 53(11):2331-42. PubMed ID: 22892156 [TBL] [Abstract][Full Text] [Related]
22. In vitro evaluation of 2-hydroxyalkylated β-cyclodextrins as potential therapeutic agents for Niemann-Pick Type C disease. Kondo Y; Tokumaru H; Ishitsuka Y; Matsumoto T; Taguchi M; Motoyama K; Higashi T; Arima H; Matsuo M; Higaki K; Ohno K; Irie T Mol Genet Metab; 2016 Jul; 118(3):214-219. PubMed ID: 27184436 [TBL] [Abstract][Full Text] [Related]
23. Early experience with compassionate use of 2 hydroxypropyl-beta-cyclodextrin for Niemann-Pick type C disease: review of initial published cases. Megías-Vericat JE; García-Robles A; Company-Albir MJ; Fernández-Megía MJ; Pérez-Miralles FC; López-Briz E; Casanova B; Poveda JL Neurol Sci; 2017 May; 38(5):727-743. PubMed ID: 28155026 [TBL] [Abstract][Full Text] [Related]
27. Necroptosis inhibition as a therapy for Niemann-Pick disease, type C1: Inhibition of RIP kinases and combination therapy with 2-hydroxypropyl-β-cyclodextrin. Cougnoux A; Clifford S; Salman A; Ng SL; Bertin J; Porter FD Mol Genet Metab; 2018 Dec; 125(4):345-350. PubMed ID: 30392741 [TBL] [Abstract][Full Text] [Related]
28. Cyclodextrin-Based Macromolecular Systems as Cholesterol-Mopping Therapeutic Agents in Niemann-Pick Disease Type C. Puglisi A; Yagci Y Macromol Rapid Commun; 2019 Jan; 40(1):e1800557. PubMed ID: 30216584 [TBL] [Abstract][Full Text] [Related]
29. Lysosomal-specific cholesterol reduction by biocleavable polyrotaxanes for ameliorating Niemann-Pick type C disease. Tamura A; Yui N Sci Rep; 2014 Mar; 4():4356. PubMed ID: 24619155 [TBL] [Abstract][Full Text] [Related]
30. Collaborative development of 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick type C1 disease. Ottinger EA; Kao ML; Carrillo-Carrasco N; Yanjanin N; Shankar RK; Janssen M; Brewster M; Scott I; Xu X; Cradock J; Terse P; Dehdashti SJ; Marugan J; Zheng W; Portilla L; Hubbs A; Pavan WJ; Heiss J; Vite CH; Walkley SU; Ory DS; Silber SA; Porter FD; Austin CP; McKew JC Curr Top Med Chem; 2014; 14(3):330-9. PubMed ID: 24283970 [TBL] [Abstract][Full Text] [Related]
31. Long-term administration of intravenous Trappsol® Cyclo™ (HP-β-CD) results in clinical benefits and stabilization or slowing of disease progression in patients with Niemann-Pick disease type C1: Results of an international 48-week Phase I/II trial. Sharma R; Hastings C; Staretz-Chacham O; Raiman J; Paucar M; Spiegel R; Murray B; Hurst B; Liu B; Kjems L; Hrynkow S Mol Genet Metab Rep; 2023 Sep; 36():100988. PubMed ID: 37670901 [TBL] [Abstract][Full Text] [Related]
32. Structure-property relationship for in vitro siRNA delivery performance of cationic 2-hydroxypropyl-β-cyclodextrin: PEG-PPG-PEG polyrotaxane vectors. Badwaik VD; Aicart E; Mondjinou YA; Johnson MA; Bowman VD; Thompson DH Biomaterials; 2016 Apr; 84():86-98. PubMed ID: 26826298 [TBL] [Abstract][Full Text] [Related]
33. Hydroxypropyl-β-cyclodextrin inhibits the development of triple negative breast cancer by enhancing antitumor immunity. Zhu M; Zhao Q; Zhang W; Xu H; Zhang B; Zhang S; Duan Y; Liao C; Yang X; Chen Y Int Immunopharmacol; 2023 Dec; 125(Pt A):111168. PubMed ID: 37939513 [TBL] [Abstract][Full Text] [Related]
34. Tolerance of chronic HDACi treatment for neurological, visceral and lung Niemann-Pick Type C disease in mice. Alam MS; Cooper B; Farris JD; Haldar K Sci Rep; 2018 Mar; 8(1):3875. PubMed ID: 29497113 [TBL] [Abstract][Full Text] [Related]
35. Expanded access with intravenous hydroxypropyl-β-cyclodextrin to treat children and young adults with Niemann-Pick disease type C1: a case report analysis. Hastings C; Vieira C; Liu B; Bascon C; Gao C; Wang RY; Casey A; Hrynkow S Orphanet J Rare Dis; 2019 Oct; 14(1):228. PubMed ID: 31639011 [TBL] [Abstract][Full Text] [Related]
36. [Intracellularly Degradable Polyrotaxanes for Therapeutic Applications]. Tamura A Yakugaku Zasshi; 2019; 139(2):143-155. PubMed ID: 30713223 [TBL] [Abstract][Full Text] [Related]
37. Nanoparticles containing β-cyclodextrin potentially useful for the treatment of Niemann-Pick C. Donida B; Raabe M; Tauffner B; de Farias MA; Machado AZ; Timm F; Kessler RG; Hammerschmidt TG; Reinhardt LS; Brito VB; Portugal RV; Bernardi A; Frozza R; Moura DJ; Giugliani R; Poletto F; Vargas CR J Inherit Metab Dis; 2020 May; 43(3):586-601. PubMed ID: 31943253 [TBL] [Abstract][Full Text] [Related]
38. Investigating the Mechanism of Cyclodextrins in the Treatment of Niemann-Pick Disease Type C Using Crosslinked 2-Hydroxypropyl-β-cyclodextrin. Carradori D; Chen H; Werner B; Shah AS; Leonardi C; Usuelli M; Mezzenga R; Platt F; Leroux JC Small; 2020 Nov; 16(46):e2004735. PubMed ID: 33079457 [TBL] [Abstract][Full Text] [Related]